Tripelennamine


Tripelennamine
Systematic (IUPAC) name
N-benzyl-N',N'-dimethyl-N- pyridin-2-yl-ethane-1,2-diamine
Identifiers
CAS number	91-81-6 154-69-8 (monohydrochloride) 22306-05-4 (hydrochloride) 57116-36-6 (maleate) 6138-56-3 (citrate)
ATC code	R06AC04
PubChem	5587
DrugBank	APRD00689
Chemical data
N₃
Mol. mass	255.358 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	Hepatic hydroxylation and glucuronidation
Half life	?
Excretion	Renal
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Tripelennamine (ethylenediamine class. It can be used in the treatment of asthma, hay fever, rhinitus and urticaria but is now less common as it has been replaced by newer antihistamines. This drug is sold in 50 mg tablets, which are usually green in colour. Tripellenamine is marketed by Novartis under the trade name Pyribenzamine.

Tripelennamine was first synthesized by Ciba, shortly after Djerassi got his BS. It was his first patent.

Side effects

Tripelennamine is mildly sedating. Other side effects can include gastrointestinal irritation, dry mouth, nausea, and dizziness.

Recreational use

Tripelennamine is sometimes abused recreationally in combination with the cyproheptadine.

v • d • e Antipruritics (Pramocaine

v • d • e Olopatadine

H1 receptor antagonists

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Tripelennamine". A list of authors is available in Wikipedia.